Table 2.
Treatment recommendation according to RS%-designated risk category
| Risk assigned using RS% | All patients | Centre 1 | Centre 2 | Centre 3 | Centre 4 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo | Chemo | Totals | Endo | Chemo | Totals | Endo | Chemo | Totals | Endo | Chemo | Totals | Endo | Chemo | Totals | |
| Low | 73 (49.0%) |
14 (9.4%) |
87 (58.4%) |
20 (57.1%) |
0 (0%) |
20 (57.1%) |
14 (70.0%) |
0 (0.0%) |
14 (70.0%) |
28 (38.4%) |
13 (17.8%) |
41 (56.2%) |
11 (52.4%) |
1 (4.8%) |
12 (57.1%) |
| Intermediate | 22 (14.8%) |
27 (18.1%) |
49 (32.9%) |
4 (11.4%) |
7 (20.0%) |
11 (31.4%) |
0 (0.0%) |
3 (15.0%) |
3 (15.0%) |
13 (17.8%) |
14 (19.2%) |
27 (37%) |
5 (23.8%) |
3 (14.3%) |
8 (38.1%) |
| High | 1 (0.7%) |
12 (8.1%) |
13 (8.7%) |
0 (0%) |
4 (11.4%) |
4 (11.4%) |
1 (5.0%) |
2 (10.0%) |
3 (15.0%) |
0 (0%) |
5 (6.8%) |
5 (6.8%) |
0 (0%) |
1 (4.8%) |
1 (4.8%) |
| Totals | 96 (64.4%) |
53 (35.6%) |
149 (100%) |
24 (68.6%) |
11 (31.4%) |
35 (100%) |
15 (75.0%) |
5 (25.0%) |
20 (100%) |
41 (56.2%) |
32 (43.8%) |
73 (100%) |
16 (76.2%) |
5 (23.8%) |
21 (100%) |
Data are presented for the whole study and individually for each centre. A total of 149/174 (85.6%) patient’s data were available for analysis (19 patients no treatment recommendation recorded, 6 were excluded for other reasons as detailed in the Results section); centre-specific case availability data are presented in Supplementary Table S1
Endo endocrine treatment only, Chemo endocrine treatment plus chemotherapy